XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.

Leukemia research ·Vol. 37 ·No. 10 ·2013-11-15

Silva Karina Lani, de Souza Paloma Silva, Nestal de Moraes Gabriela, Moellmann-Coelho Arthur, Vasconcelos Flavia da Cunha, Maia Raquel Ciuvalschi

Abstract

P-glycoprotein (Pgp) and XIAP co-expression has been discussed in the process of the acquisition of multidrug resistance (MDR) in cancer. Here, we evaluated XIAP and Pgp expression in chronic myeloid leukemia (CML) samples, showing a positive correlation between them. Furthermore, we evaluated the effects of imatinib in XIAP and Pgp expression using CML cell lines K562 (Pgp(-)) and K562-Lucena (Pgp(+)). Imatinib increased XIAP and Pgp expression in K562-Lucena cells, while in K562 cells a downregulation of these proteins was observed, suggesting that imatinib induces an increment of MDR phenotype of CML cells that previously exhibit high levels of Pgp/XIAP co-expression.

Keywords

CML CSA Chronic myeloid leukemia IAPs IC(50) Imatinib MDR MFI Multidrug resistance P-glycoprotein Pgp RFI Rho-123 Survivin VRP XIAP chronic myeloid leukemia concentration achieving 50% inhibition of cell growth cyclosporin A inhibitor of apoptosis proteins mean of fluorescence intensity multidrug resistance ratio of mean of fluorescence intensity rhodamine-123 verapamil

Article Info

Journal

Leukemia research

Abbr.

Leuk Res

ISSN

0145-2126

DOI

10.1016/j.leukres.2013.06.014

Published

2013-11-15

Indexed

2013-09-09

Updated

2015-11-19

Language

English

Country/Region

England

NLM ID

7706787

External Links

PubMed source DOI: 10.1016/j.leukres.2013.06.014 View journal details

Analysis Services

XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.

Contact

WeChat Official Account